Cantor Fitzgerald Issues Negative Forecast for FULC Earnings

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) – Stock analysts at Cantor Fitzgerald dropped their FY2025 earnings per share (EPS) estimates for Fulcrum Therapeutics in a research note issued on Thursday, October 30th. Cantor Fitzgerald analyst K. Kluska now anticipates that the company will earn ($1.19) per share for the year, down from their previous forecast of ($1.18). The consensus estimate for Fulcrum Therapeutics’ current full-year earnings is ($0.16) per share. Cantor Fitzgerald also issued estimates for Fulcrum Therapeutics’ FY2026 earnings at ($1.11) EPS.

Several other analysts have also commented on FULC. HC Wainwright reissued a “buy” rating and set a $12.00 price target on shares of Fulcrum Therapeutics in a research report on Monday, October 20th. Leerink Partners set a $20.00 target price on shares of Fulcrum Therapeutics and gave the stock an “outperform” rating in a research note on Tuesday, October 21st. Royal Bank Of Canada upped their price target on shares of Fulcrum Therapeutics from $5.00 to $7.00 and gave the company a “sector perform” rating in a research note on Thursday, October 30th. Wall Street Zen cut shares of Fulcrum Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Fulcrum Therapeutics in a report on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $13.00.

Fulcrum Therapeutics Price Performance

Shares of NASDAQ FULC opened at $9.02 on Monday. Fulcrum Therapeutics has a 1-year low of $2.32 and a 1-year high of $10.11. The business has a fifty day moving average price of $8.25 and a 200 day moving average price of $7.11. The stock has a market capitalization of $488.16 million, a P/E ratio of -7.64 and a beta of 3.02.

Fulcrum Therapeutics (NASDAQ:FULC) last issued its earnings results on Wednesday, October 29th. The company reported ($0.31) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.02).

Institutional Investors Weigh In On Fulcrum Therapeutics

Hedge funds have recently added to or reduced their stakes in the business. Farther Finance Advisors LLC raised its stake in shares of Fulcrum Therapeutics by 108.3% during the 3rd quarter. Farther Finance Advisors LLC now owns 7,112 shares of the company’s stock valued at $65,000 after buying an additional 3,697 shares during the last quarter. Russell Investments Group Ltd. grew its stake in Fulcrum Therapeutics by 4,209.3% during the 2nd quarter. Russell Investments Group Ltd. now owns 9,308 shares of the company’s stock worth $64,000 after purchasing an additional 9,092 shares in the last quarter. Jump Financial LLC acquired a new stake in Fulcrum Therapeutics in the first quarter valued at approximately $30,000. Y Intercept Hong Kong Ltd acquired a new stake in shares of Fulcrum Therapeutics in the 3rd quarter valued at $104,000. Finally, Brooklyn Investment Group lifted its holdings in Fulcrum Therapeutics by 209.7% during the 1st quarter. Brooklyn Investment Group now owns 12,190 shares of the company’s stock worth $35,000 after buying an additional 8,254 shares during the last quarter. 89.83% of the stock is owned by hedge funds and other institutional investors.

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.